Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Multiple Myeloma
Multiple Myeloma
All-Oral Regimen May Become a New Standard of Care in Advanced Multiple Myeloma
Dana Taylor
Play Video
Multiple Myeloma
American Society of Hematology 2016: Multiple Myeloma Highlights
Play Video
Multiple Myeloma
ASCO 2017: Multiple Myeloma Highlights
Play Video
Multiple Myeloma
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Play Video
Multiple Myeloma
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
Wayne Kuznar
Wayne Kuznar
Play Video
Multiple Myeloma
CAR T-Cell Immunotherapy Makes Strides in Multiple Myeloma, with Durable Remission
Wayne Kuznar
Play Video
Multiple Myeloma
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
Chase Doyle
Chase Doyle
Play Video
Multiple Myeloma
Consistent Benefit Over Time in Elotuzumab Studies
Dana Taylor
Play Video
Multiple Myeloma
Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma
Chase Doyle
Play Video
Multiple Myeloma
Daratumumab Improves Overall Survival in Multiple Myeloma
Dana Taylor
Play Video
1
2
3
4
Page 1 of 6
Results 1 - 10 of 52